PL362477A1 - Inhibitory reduktazy HMG-CoA i sposób leczenia - Google Patents

Inhibitory reduktazy HMG-CoA i sposób leczenia

Info

Publication number: PL362477A1
Authority: PL; Poland
Prior art keywords: hmg; medicaments; treatment; related diseases; coa reductase
Prior art date: 2000-06-15

Application number

PL01362477A

Other languages

English (en)

Inventor

Jeffrey A. Robl

Bang-Chi Chen

Chong-Qing Sun

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-15

Filing date

2001-06-12

Publication date

2004-11-02

2001-06-12 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-11-02 Publication of PL362477A1 publication Critical patent/PL362477A1/pl

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
235000012000 cholesterol Nutrition 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Virology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

PL01362477A 2000-06-15 2001-06-12 Inhibitory reduktazy HMG-CoA i sposób leczenia PL362477A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21159400P	2000-06-15	2000-06-15
PCT/US2001/018868 WO2001096311A2 (en)	2000-06-15	2001-06-12	Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Publications (1)

Publication Number	Publication Date
PL362477A1 true PL362477A1 (pl)	2004-11-02

Family

ID=22787566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01362477A PL362477A1 (pl)	2000-06-15	2001-06-12	Inhibitory reduktazy HMG-CoA i sposób leczenia

Country Status (20)

Country	Link
US (1)	US20020028826A1 (pl)
EP (1)	EP1294696A2 (pl)
JP (1)	JP2004503541A (pl)
KR (1)	KR20030010720A (pl)
CN (1)	CN1436174A (pl)
AR (1)	AR028732A1 (pl)
AU (1)	AU2001266860A1 (pl)
BR (1)	BR0111571A (pl)
CA (1)	CA2412979A1 (pl)
CZ (1)	CZ20023931A3 (pl)
EC (1)	ECSP024386A (pl)
HU (1)	HUP0302955A3 (pl)
IL (1)	IL152718A0 (pl)
MX (1)	MXPA02012415A (pl)
NO (1)	NO20026011L (pl)
PE (1)	PE20011364A1 (pl)
PL (1)	PL362477A1 (pl)
UY (1)	UY26776A1 (pl)
WO (1)	WO2001096311A2 (pl)
ZA (1)	ZA200210102B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110196039A9 (en) *	1994-10-05	2011-08-11	Kaesemeyer Wayne H	Controlled release arginine formulations
JP2004506008A (ja) *	2000-08-15	2004-02-26	ファイザー・プロダクツ・インク	治療コンビネーション
IL158525A0 (en) *	2001-06-06	2004-05-12	Bristol Myers Squibb Co	A process for preparing chiral diol sulfone derivatives
ES2284887T3 (es)	2001-07-11	2007-11-16	Boehringer Ingelheim Pharmaceuticals Inc.	Metodos para tratar enfermedades transmitidas por citocinas.
US6869975B2 (en)	2001-09-14	2005-03-22	Tularik Inc.	Linked biaryl compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
WO2003090723A1 (en) *	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Modified-release vasopeptidase inhibitor formulation, combinations and method
US20050192245A1 (en) *	2002-07-18	2005-09-01	Sankyo Company, Limited	Medicinal composition for treating arteriosclerosis
MXPA05000726A (es) *	2002-07-18	2005-04-08	Sankyo Co	Composicion medicinal para tratar arteriosclerosis.
EP1542989B1 (en) *	2002-07-31	2007-04-18	Critical Outcome Technologies, Inc.	Protein tyrosine kinase inhibitors
GB0220885D0 (en) *	2002-09-09	2002-10-16	Novartis Ag	Organic compounds
AU2003273675A1 (en) *	2002-10-09	2004-05-04	Wayne R. Danter	Protein tyrosine kinase inhibitors
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
NZ577031A (en)	2003-05-30	2010-09-30	Ranbaxy Lab Ltd	Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US20070161700A1 (en)	2004-12-28	2007-07-12	Kowa Company, Ltd.	Inhibitor for the formation of y-secretase complex
US20080312189A1 (en) *	2004-03-05	2008-12-18	Eisai Co., Ltd.	Cadasil Treatment with Cholinesterase Inhibitors
WO2005099823A1 (en) *	2004-04-14	2005-10-27	Warner-Lambert Company Llc	Therapeutic combination for treatment of alzheimers disease
JP4880591B2 (ja)	2004-06-04	2012-02-22	テバファーマシューティカルインダストリーズリミティド	イルベサルタンを含む医薬組成物
US20070112050A1 (en) *	2005-04-12	2007-05-17	Psivida Inc.	HMGCoA reductase inhibitor combinations and uses thereof
EP1909848A2 (en) *	2005-08-01	2008-04-16	PSivida Inc.	HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
WO2007054896A1 (en) *	2005-11-08	2007-05-18	Ranbaxy Laboratories Limited	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN102743755B (zh) *	2006-02-07	2015-01-14	持田制药株式会社	预防中风复发的组合物
ES2475162T3 (es) *	2006-02-27	2014-07-10	Targeted Molecular Diagnostics, Llc	Métodos para predecir la toxicidad cardíaca antes y después del tratamiento con inhibidores de tirosina cinasa
WO2007111027A1 (ja) *	2006-03-29	2007-10-04	Kowa Co., Ltd.	トリグリセリド低下剤及び高インスリン血症改善剤
WO2008059519A2 (en) *	2006-09-25	2008-05-22	Glenmark Pharmaceuticals Limited	A process for the preparation of intermediates of rosuvastatin
EP2121681B1 (en)	2007-01-11	2015-04-15	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
US8404275B2 (en)	2007-07-01	2013-03-26	Vitalis Llc	Combination tablet with chewable outer layer
KR100900044B1 (ko) *	2007-07-05	2009-06-01	한국식품연구원	3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
EP2225226B1 (en)	2007-12-26	2016-08-17	Critical Outcome Technologies, Inc.	Compounds and their use in a method for treatment of cancer
EP3023426A1 (en)	2008-07-17	2016-05-25	Critical Outcome Technologies, Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) *	2009-03-06	2012-01-16	가톨릭대학교 산학협력단	알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
US8987272B2 (en)	2010-04-01	2015-03-24	Critical Outcome Technologies Inc.	Compounds and method for treatment of HIV
MX2013000824A (es) *	2010-07-21	2013-10-28	Nucitec Sa De Cv	Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US8877221B2 (en)	2010-10-27	2014-11-04	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en)	2010-10-27	2015-08-18	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising statins
HUE025730T2 (en)	2011-01-18	2016-04-28	Dsm Sinochem Pharm Nl Bv	A method for producing statins using a base
MX2013008285A (es)	2011-01-18	2013-09-13	Dsm Sinochem Pharm Bv	Procedimiento para la preparacion de diolsulfonas.
WO2012098050A1 (en)	2011-01-18	2012-07-26	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Methyltetrazole sulfides and sulfones
WO2012170417A2 (en)	2011-06-06	2012-12-13	Warsaw Orthopedic, Inc.	Methods and compositions to enhance bone growth comprising a statin
EP2770978B1 (en)	2011-10-28	2018-01-10	Vitalis LLC	Anti-flush compositions
EP2788342B1 (en)	2011-12-09	2018-01-24	DSM Sinochem Pharmaceuticals Netherlands B.V.	Process for the preparation of a statin precursor
MX363563B (es)	2011-12-09	2019-03-27	Dsm Sinochem Pharm Nl Bv	Proceso para la preparación de un tioprecursor de estatinas.
JP6041985B2 (ja) *	2012-06-08	2016-12-14	ミレファインケミカルカンパニーリミテッド	結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN112159403B (zh)	2020-09-30	2022-04-15	复旦大学	一种用于合成他汀类药物的关键中间体的制备方法
CN114394961A (zh) *	2021-12-24	2022-04-26	江苏阿尔法药业股份有限公司	用臭氧做氧化剂制备瑞舒伐他汀钙中间体的方法
CN114213350B (zh) *	2021-12-29	2024-03-19	江苏福瑞康泰药业有限公司	一种他汀类药物中间体的制备方法
CN114437052B (zh) *	2021-12-31	2024-03-29	江苏阿尔法集团福瑞药业(宿迁)有限公司	一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) *	2022-03-16	2022-06-10	江苏省农业科学院	一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors

2001
- 2001-06-06 US US09/875,218 patent/US20020028826A1/en not_active Abandoned
- 2001-06-12 WO PCT/US2001/018868 patent/WO2001096311A2/en not_active Ceased
- 2001-06-12 HU HU0302955A patent/HUP0302955A3/hu unknown
- 2001-06-12 KR KR1020027017087A patent/KR20030010720A/ko not_active Withdrawn
- 2001-06-12 MX MXPA02012415A patent/MXPA02012415A/es unknown
- 2001-06-12 CN CN01811219A patent/CN1436174A/zh active Pending
- 2001-06-12 JP JP2002510454A patent/JP2004503541A/ja active Pending
- 2001-06-12 IL IL15271801A patent/IL152718A0/xx unknown
- 2001-06-12 CA CA002412979A patent/CA2412979A1/en not_active Abandoned
- 2001-06-12 PL PL01362477A patent/PL362477A1/pl not_active Application Discontinuation
- 2001-06-12 CZ CZ20023931A patent/CZ20023931A3/cs unknown
- 2001-06-12 BR BR0111571-5A patent/BR0111571A/pt not_active IP Right Cessation
- 2001-06-12 AU AU2001266860A patent/AU2001266860A1/en not_active Abandoned
- 2001-06-12 EP EP01944449A patent/EP1294696A2/en not_active Withdrawn
- 2001-06-15 UY UY26776A patent/UY26776A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102885A patent/AR028732A1/es not_active Application Discontinuation
- 2001-06-15 PE PE2001000579A patent/PE20011364A1/es not_active Application Discontinuation
2002
- 2002-12-12 ZA ZA200210102A patent/ZA200210102B/en unknown
- 2002-12-12 EC EC2002004386A patent/ECSP024386A/es unknown
- 2002-12-13 NO NO20026011A patent/NO20026011L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR028732A1 (es)	2003-05-21
PE20011364A1 (es)	2002-02-27
WO2001096311A3 (en)	2002-07-11
HUP0302955A2 (hu)	2003-12-29
NO20026011L (no)	2003-02-12
JP2004503541A (ja)	2004-02-05
AU2001266860A1 (en)	2001-12-24
WO2001096311A2 (en)	2001-12-20
ECSP024386A (es)	2003-03-10
KR20030010720A (ko)	2003-02-05
US20020028826A1 (en)	2002-03-07
CN1436174A (zh)	2003-08-13
UY26776A1 (es)	2002-01-31
CZ20023931A3 (cs)	2003-03-12
EP1294696A2 (en)	2003-03-26
BR0111571A (pt)	2003-07-01
HUP0302955A3 (en)	2005-08-29
ZA200210102B (en)	2004-03-12
CA2412979A1 (en)	2001-12-20
IL152718A0 (en)	2003-06-24
NO20026011D0 (no)	2002-12-13
MXPA02012415A (es)	2003-06-06

Legal Events

Date	Code	Title	Description
2009-03-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL362477A1 (pl)	2004-11-02	Inhibitory reduktazy HMG-CoA i sposób leczenia
AU2002251841A1 (en)	2002-08-12	Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002241520A1 (en)	2003-03-03	Blood assessment of injury
AU2004208615B2 (en)	2007-05-03	Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2003256253A1 (en)	2003-12-02	Aerosol for medical treatment and methods
SI1487541T1 (sl)	2009-02-28	Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003216592A8 (en)	2003-10-20	Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
AU2002248319A1 (en)	2002-08-12	Pharmaceutical composition for the prevention and treatment of scar tissue
HUP0401605A3 (en)	2012-09-28	Integrin inhibitors for the treatment of eye diseases
AU2001269314A1 (en)	2002-01-21	Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU2002237667A1 (en)	2002-05-27	Methods for the treatment and prevention of urinary stone disease
AU2001249262A1 (en)	2001-10-03	Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2002339439A1 (en)	2003-02-24	Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
AU3270301A (en)	2001-05-30	Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
HUP0303306A3 (en)	2005-12-28	Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2003262229A1 (en)	2004-03-11	Preventive and/or therapeutic drugs for asthma
AU2432001A (en)	2001-06-25	Treatment of mental conditions including depression
AU2003291368A1 (en)	2004-06-03	Compounds for the treatment of tobacco dependence and withdrawal
AU5680900A (en)	2001-01-31	Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU2001271284A1 (en)	2001-12-17	Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2003213898A1 (en)	2003-10-13	Prevention and treatment of mycoplasma-associated diseases
AU2001296224A1 (en)	2002-02-18	Compositions and methods for the therapy and diagnosis of pancreatic cancer
HK1051682A (en)	2003-08-15	Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2001267165A1 (en)	2002-01-14	Prevention and treatment of mycoplasma-associated diseases
AU2002351798A1 (en)	2003-05-12	Methods and dosage forms for improving the bioavailability of therapeutic agents